ReviewClinical pharmacokinetics2008
Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
Review in Clinical pharmacokinetics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidelines for clinical evaluation of anti-cancer drugs.Cancer science · 2021Guideline
- Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.Clinical pharmacokinetics · 2016Trial
- Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.Investigational new drugs · 2011Trial
- A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Pharmacometrics: A New Era of Pharmacotherapy and Drug Development in Low- and Middle-Income Countries.Advances in pharmacological and pharmaceutical sciences · 2023Review
- The effect of a Clinical Decision Support System on the frequency of dose adjustments of anticancer drugs in case of renal or hepatic dysfunction.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2022Article
- Comparative pharmacokinetics of valproic acid among Pakistani and South Korean patients: A population pharmacokinetic study.PloS one · 2022Article
- Article
- Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir.Investigational new drugs · 2020Article
- Optimization of Cancer Treatment in the Frequency Domain.The AAPS journal · 2019Article
- Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions.CPT: pharmacometrics & systems pharmacology · 2018Article
- Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach.Oncotarget · 2018Article
- Pharmacokinetics of Chlorin e₆-Cobalt Bis(Dicarbollide) Conjugate in Balb/c Mice with Engrafted Carcinoma.International journal of molecular sciences · 2017Article
- Frequency-Domain Response Analysis for Quantitative Systems Pharmacology Models.CPT: pharmacometrics & systems pharmacology · 2017Article
- Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.The oncologist · 2016Review
- Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Clinical pharmacokinetics · 2013Review
- Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.CPT: pharmacometrics & systems pharmacology · 2013Article
- Pharmacokinetic considerations for antibody drug conjugates.Pharmaceutical research · 2012Review
- Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer.Head & neck · 2009Article
- Pharmacokinetics and dosage adjustment in patients with renal dysfunction.European journal of clinical pharmacology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population pharmacokinetic and pharmacodynamic analysis is an important tool to support optimal treatment in clinical oncology. The population approach is suitable to explain variability between patients and to establish relationships between drug exposure and a relevant pharmacodynamic parameter. This can facilitate the selection of dosing schedules, the development of strategies for dose individualization and the application of therapeutic drug monitoring of anticancer agents. This review discusses the role of population pharmacokinetics and pharmacodynamics in clinical oncology to enhance the efficiency of drug development and to support the development of safe and effective dosing regimens for optimal treatment of cancer patients. An overview of published population studies of investigational anticancer agents and established treatment regimens is presented.
Indexed as
Identifiers
18611060What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.